Floatz logo

gq1001

HER2-positive Biliary Tract Cancer

GeneQuantum Healthcare (Suzhou) Co., Ltd.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

84 Active assets in the HER2-positive Biliary Tract Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 3BB
Epirubicin
Merck Sharp & Dohme LLC
Phase 3BB
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Capecitabine
Zhejiang Cancer Hospital
Phase 2BB
FLUOROURACILUM
Shenzhen Xinhe Biomedical
Phase 2BB

View all 50 →

Same molecule, other indications

gq1001 is also rated in:

HER2-Positive Advanced Solid TumorDormant
CC
Indicative ·
43 / 100
View asset →
HER2 positive breast carcinomaDormant
NR
Indicative ·
/ 100
View asset →
salivary gland carcinomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →